- Trials with a EudraCT protocol (48)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
48 result(s) found for: Complete heart block.
Displaying page 1 of 3.
EudraCT Number: 2017-002475-26 | Sponsor Protocol Number: GD2CAR01 | Start Date*: 2017-12-22 | |||||||||||
Sponsor Name:IRCCS Ospedale Pediatrico Bambino Gesù | |||||||||||||
Full Title: Phase I/II study of anti-GD2 Chimeric Antigen Receptor-Expressing T cells in pediatric patients affected by High Risk and/or relapsed/refractory Neuroblastoma | |||||||||||||
Medical condition: High Risk and/or relapsed/refractory Neuroblastoma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002519-40 | Sponsor Protocol Number: CHL.2/01-2014/M | Start Date*: 2015-08-17 | |||||||||||
Sponsor Name:Sintetica S.A. | |||||||||||||
Full Title: A prospective, randomised, non-inferiority study of Chloroprocaine 2% and the active control Ropivacaine 0.75% (AstraZeneca) in ultrasound-guided axillary nerve block for short-duration distal uppe... | |||||||||||||
Medical condition: Local anaesthesia by axillary nerve block | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000656-18 | Sponsor Protocol Number: 2042015 | Start Date*: 2018-11-09 | |||||||||||
Sponsor Name:SINTETICA SA | |||||||||||||
Full Title: Randomized, multi-center, double-blind, two-armed, parallel active groups, prospective trial, to evaluate, in pediatric population undergoing 'Calcaneo stop' surgery or Inguinal hernia repair, the ... | |||||||||||||
Medical condition: Pediatric patients undergoing surgery of flatfoot or inguinal hernia | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) ES (Restarted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001763-36 | Sponsor Protocol Number: CSPP100A2347 | Start Date*: 2006-12-04 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A randomized, double-blind, parallel-group, placebo-controlled, multinational clinical trial to evaluate the efficacy of Aliskiren and valsartan versus placebo in lowering levels on NT-proBNP in st... | ||
Medical condition: Hypertension | ||
Disease: | ||
Population Age: | Gender: Male, Female | |
Trial protocol: NL (Completed) SE (Completed) CZ (Completed) BE (Completed) DE (Completed) HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-004060-40 | Sponsor Protocol Number: AGO15 | Start Date*: 2008-03-13 |
Sponsor Name:Studienzentrale AGO Austria | ||
Full Title: Phase II multicenter trial of the Austrian AGO of the combination of liposomal Doxorubicin (Myocet®) and Carboplatin in primary advanced or metastatic and recurrent endometrial cancer | ||
Medical condition: primary advanced or recurrent/metastatic endometrial cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-001095-77 | Sponsor Protocol Number: AC4105211 | Start Date*: 2008-09-19 |
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||
Full Title: A randomised, double-blind, placebo-controlled, dose ascending, 2-cohort, parallel group study to examine the safety, tolerability and pharmacokinetics of once-daily inhaled doses of GSK573719 form... | ||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | ||
Disease: | ||
Population Age: | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-001245-89 | Sponsor Protocol Number: BDR4580 | Start Date*: 2015-04-13 | |||||||||||
Sponsor Name:Sanofi-aventis | |||||||||||||
Full Title: Relative bioavailability study between 75 mg tablet and 75 mg solution of Clopidogrel (SR25990C) after single oral administration to young healthy men. Open, crossover, randomized and monocenter study | |||||||||||||
Medical condition: Young healthy men (intended indication cardiovascular disease) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005499-20 | Sponsor Protocol Number: RM21 | Start Date*: 2022-07-05 |
Sponsor Name:Research Maatschap Cardiologen Rotterdam Zuid | ||
Full Title: COMPARE STEMI ONE- Comparison Of reduced DAPT followed by P2Y12 inhibitor Monotherapy with Prasugrel vs stAndard Regimen in STEMI patients treated with OCT-guided vs aNgio-guided completE revascul... | ||
Medical condition: ST elevated myocard infarction followed by PCI | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002479-33 | Sponsor Protocol Number: R2377 | Start Date*: 2020-03-02 | ||||||||||||||||||||||||||
Sponsor Name:Hull University Teaching Hospitals NHS Trust | ||||||||||||||||||||||||||||
Full Title: A parallel group, double-blind, randomised, placebo-controlled trial comparing the effectiveness and cost effectiveness of low dose oral modified release morphine versus placebo on patient-reported... | ||||||||||||||||||||||||||||
Medical condition: Chronic breathlessness due to cardiac, respiratory disease or cancer. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000439-24 | Sponsor Protocol Number: NORA Trial | Start Date*: 2007-02-21 | |||||||||||
Sponsor Name:OSPEDALE S. RAFFAELE | |||||||||||||
Full Title: NORA TRIAL (oral Navelbine in adjuvabt):multicenter,prospective,phase II, randomized clinical trial concerning about adjuvant chemioterapy with cisplatino and vinorelbine according to an advanced s... | |||||||||||||
Medical condition: patients underwent complete surgery for non small cel lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004905-15 | Sponsor Protocol Number: DNDi-FEX-12-CH | Start Date*: 2017-09-13 |
Sponsor Name:Drugs for Neglected Diseases initiative (DNDi) | ||
Full Title: Phase 2 Randomized, Multicenter, Double-blinded Safety and Efficacy Study to Evaluate Oral Fexinidazole Dosing Regimens for the Treatment of Adult Patients with Chronic Indeterminate Chagas Disease | ||
Medical condition: Chagas disease (CD) is a disease caused by Trypanosoma cruzi, ranking among the world’s most neglected diseases. There is significant associated morbidity and mortality, particularly in chronic ph... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-001161-16 | Sponsor Protocol Number: ML28879 | Start Date*: 2013-09-12 |
Sponsor Name:ROCHE SPA | ||
Full Title: NATIONAL PHASE IIIB PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, OPEN LABEL STUDY TO ASSESS THE SAFETY OF SUBCUTANEOUS TRASTUZUMAB AND MOLECULAR BIOMARKERS IN PATIENTS WITH EARLY AND LOCAL... | ||
Medical condition: EARLY AND LOCALLY ADVANCED HER2-POSITIVE BREAST CANCER | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-005478-66 | Sponsor Protocol Number: PDY5808 | Start Date*: 2006-02-09 | |||||||||||
Sponsor Name:Sanofi-Synthelabo Recherche | |||||||||||||
Full Title: Effect of a single oral 120 µg dose of SSR150106XB compared to placebo on the assessment of post dental surgical pain after extraction of an impacted or partially impacted third molar in 90 male an... | |||||||||||||
Medical condition: Men and women who are to undergo elective surgery for extraction of at least one lower impacted or partially impacted third molar | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005743-14 | Sponsor Protocol Number: 15.0214 | Start Date*: 2016-04-15 |
Sponsor Name:St Georges University Hospital NHS Foundation Trust | ||
Full Title: Fetal Atrial Flutter & Supraventricular Tachycardia (FAST) Therapy Trial | ||
Medical condition: Fetal atrial flutter without hydrops, supraventricular tachycardia without hydrops and supraventricular tachycardia with hydrops | ||
Disease: | ||
Population Age: In utero, Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003613-19 | Sponsor Protocol Number: APHP210303 | Start Date*: 2021-12-07 |
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | ||
Full Title: AbataCept for the treatment of immune-cHeckpoint inhibitors induced mYocarditiS | ||
Medical condition: All adult patients with cancer (all cancer types) treated by immune checkpoint inhibitors (anti-PD1, anti-PDL1, anti-CTLA4 monotherapies or combination) and presenting drug-induced myocarditis. The... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004897-32 | Sponsor Protocol Number: WO40324 | Start Date*: 2018-06-04 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A phase III, randomized, multicenter, open-label, two-arm study to evaluate the pharmacokinetics, efficacy, and safety of subcutaneous administration of the fixed-dose combination of pertuzumab and... | |||||||||||||
Medical condition: Human epidermal growth factor receptor 2 (HER2)-positive Early Breast Cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) BE (Completed) CZ (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000762-11 | Sponsor Protocol Number: 62113-55115 | Start Date*: 2014-10-20 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC) | |||||||||||||
Full Title: A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) after stabilization or response to doxoru... | |||||||||||||
Medical condition: High Grade Undifferentiated Uterine Sarcoma (HGUS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) IT (Completed) ES (Completed) DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006240-63 | Sponsor Protocol Number: MAB104958 | Start Date*: 2007-06-11 |
Sponsor Name:GlaxoSmithKline Research and Development | ||
Full Title: A study to assess the pharmacokinetics of single escalating doses of inhaled GSK961081 DPI (a dual pharmacophore) in healthy subjects (Part 1) and a randomised, double-blind, double dummy, crossove... | ||
Medical condition: Chronic obstructive pulmonary disease (COPD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-004893-14 | Sponsor Protocol Number: ASR115645 | Start Date*: 2016-08-03 |
Sponsor Name:GlaxoSmithKline Research & Development | ||
Full Title: A Randomised, Multi-centre, Double-blind, Double-dummy, two way cross-over, twelve weeks noninferiority study to evaluate the efficacy, safety and tolerability of combination dry powder Fluticasone... | ||
Medical condition: Asthma | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2015-005454-35 | Sponsor Protocol Number: RG_15-235 | Start Date*: 2016-09-23 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: Risk-stratified sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-novo post-transplant Lymphoproliferative disorder (PTLD) | |||||||||||||
Medical condition: Post-transplant lymphoproliferative disorder | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
